About Climb Bio, Inc.

Climb Bio, Inc. is a biopharmaceutical firm dedicated to crafting therapeutic solutions for inflammatory diseases driven by autoimmune responses. Its primary investigational asset is budoprutug, an anti-CD19 monoclonal antibody. This treatment is being advanced for a range of autoimmune conditions, including systemic lupus erythematosus, lupus nephritis, immune thrombocytopenia, and membranous nephropathy. The entity, established in 2018, officially rebranded as Climb Bio, Inc. in October 2024, having previously operated under the name Eliem Therapeutics, Inc. Its corporate headquarters are situated in Wilmington, Delaware.

Exchange: NASDAQ
Sector: Healthcare
Industry: Biotechnology
Employees: 28
Price: $12.86
Previous close: $12.52
Market capitalization: $716.93M
Volume: 2,141,737
P/E ratio: -15.08
52-week low: $1.54
52-week high: $18.33

Additional performance and financial-statement views load in the interactive application.

Market information is provided for research and visualization and is not investment advice.